Search
Search
About
Log in
Join
Experiences with
Targeted therapy
Posts
Communities
16,233 public posts
Filter results
Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
"We are enthusiastic about commencing GMP manufacturing for our prostate cancer clinical candidate, continuing our efforts at transforming
targeted
cancer
therapy
via the introduction of potent personalized cellular cancer vaccines" https://www.biospace.com/article/releases/breaking-ground-in-prostate-cancer-briacell-announces-lead-prostate-cancer-candidate-bria-pros-initiates-gmp-manufacturing
"We are enthusiastic about commencing GMP manufacturing for our prostate cancer clinical candidate, continuing our efforts at transforming
targeted
cancer
therapy
via the introduction of potent personalized cellular cancer vaccines" https://www.biospace.com/article/releases/breaking-ground-in-prostate-cancer-briacell-announces-lead-prostate-cancer-candidate-bria-pros-initiates-gmp-manufacturing
Maxone73
in
Advanced Prostate Cancer
4 months ago
I don't want to start treatment ever, however I know that I probably will at some point.
My Oncologist is trying to bully me into
Targeted
Therapy
Trials & I have seen too much suffering with Cancer Treatments in my personal & professional life as an RN over 31yrs. I just don't want to live the rest of my life feeling worst.
My Oncologist is trying to bully me into
Targeted
Therapy
Trials & I have seen too much suffering with Cancer Treatments in my personal & professional life as an RN over 31yrs. I just don't want to live the rest of my life feeling worst.
CoachVera55
in
CLL Support
1 year ago
New bone met
I have a consult with radiation oncologist on Wednesday and wanted to ask if any of you have had very
targeted
radiation
therapy
to one small new spot on bone when your systemic treatment (Ibrance and Letrozole) is still working on other mets. I saw there is SBRT and IMRT.
I have a consult with radiation oncologist on Wednesday and wanted to ask if any of you have had very
targeted
radiation
therapy
to one small new spot on bone when your systemic treatment (Ibrance and Letrozole) is still working on other mets. I saw there is SBRT and IMRT.
Trissh
in
SHARE Metastatic Breast Cancer
9 months ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
What next option available if CDK4/6 get failed
Cycle 5FEC and 1 Cycle of Docetaxel) than surgery (lumpectomy) again 2 cycle of 5FEC chemo 2016 march NED put on tamoxifen 20 mg regular check up and in 2021 it relapsed in operated breast spread to right axillary, mediastinal, iliac bone and liver again start with zoledronic acid 4mg letrozole with
targeted
Cycle 5FEC and 1 Cycle of Docetaxel) than surgery (lumpectomy) again 2 cycle of 5FEC chemo 2016 march NED put on tamoxifen 20 mg regular check up and in 2021 it relapsed in operated breast spread to right axillary, mediastinal, iliac bone and liver again start with zoledronic acid 4mg letrozole with
targeted
Deepak1965
in
Breast Cancer India
1 year ago
Latest Treatments for Advanced Prostate Cancer
[/i] [i]Olaparib (Lynparza): This is a type of
targeted
therapy
that belongs to a class of drugs called PARP inhibitors. PARP inhibitors block an enzyme called PARP, which helps repair damaged DNA in cells.
[/i] [i]Olaparib (Lynparza): This is a type of
targeted
therapy
that belongs to a class of drugs called PARP inhibitors. PARP inhibitors block an enzyme called PARP, which helps repair damaged DNA in cells.
NecessarilySo
in
Advanced Prostate Cancer
11 months ago
The TheraPb clinical trial of targeted alpha therapy for prostate cancer is running for three years with plans for up to 100 patients
The
targeted
alpha
therapy
for prostate cancer study is one of just a number of ground-breaking theranostics trials underway. The TheraPb clinical trial of
targeted
alpha
therapy
for prostate cancer is running for three years with plans for up to 100 patients to participate.
The
targeted
alpha
therapy
for prostate cancer study is one of just a number of ground-breaking theranostics trials underway. The TheraPb clinical trial of
targeted
alpha
therapy
for prostate cancer is running for three years with plans for up to 100 patients to participate.
Seasid
in
Advanced Prostate Cancer
1 month ago
New results soon (hopefully): A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Not the latest, but some more insight, since results should be on their way https://clinicaltrials.ucsf.edu/trial/NCT03575819 but they are already working on another CD46-
targeted
alpha
therapy
based on YS5, a radioimmunoconjugate.
Not the latest, but some more insight, since results should be on their way https://clinicaltrials.ucsf.edu/trial/NCT03575819 but they are already working on another CD46-
targeted
alpha
therapy
based on YS5, a radioimmunoconjugate.
Maxone73
in
Advanced Prostate Cancer
7 months ago
Why not give Hyperbaric Oxygen Therapy (HBOT) as Adjunctive Therapy a Try?
Gleevec was the first
targeted
therapy
drug in the world. It destroyed cancer cells and left healthy cells intact. Before Gleevec the five year survival rate for CML was only 22%. Gleevec FDA approval (2001) is the shortest on record. TASIGNA was approved in 2007.
Gleevec was the first
targeted
therapy
drug in the world. It destroyed cancer cells and left healthy cells intact. Before Gleevec the five year survival rate for CML was only 22%. Gleevec FDA approval (2001) is the shortest on record. TASIGNA was approved in 2007.
Isthistheone
in
Cure Parkinson's
9 months ago
IDH2 R172 Linked With Improved Survival in Myeloid Neoplasms from April 14, 2023 Hematology Advisor- More r/t AML than MPNs- look below it..
“In an era of
targeted
therapy
, with IDH1 and IDH2 small-molecule inhibitors receiving FDA approval and entering routine clinical use, resolution of the clinicopathologic features and survival expectations associated with distinct genetic subtypes of IDH-mutated myeloid neoplasia is imperative to aid
“In an era of
targeted
therapy
, with IDH1 and IDH2 small-molecule inhibitors receiving FDA approval and entering routine clinical use, resolution of the clinicopathologic features and survival expectations associated with distinct genetic subtypes of IDH-mutated myeloid neoplasia is imperative to aid
PhysAssist
in
MPN Voice
1 year ago
exciting research
https://www.mpnresearchfoundation.org/news/nanobody-based-
targeted
-
therapy
/?utm_source=facebook&utm_medium=social+media&utm_campaign=2023+news+post&fbclid=IwAR3Owcpn9YIHBNiqP-S7irL8CLX5TG1jYRxExk5H1Ll-xpJqCax3DMkz9dY&mibextid=Zxz2cZ
https://www.mpnresearchfoundation.org/news/nanobody-based-
targeted
-
therapy
/?utm_source=facebook&utm_medium=social+media&utm_campaign=2023+news+post&fbclid=IwAR3Owcpn9YIHBNiqP-S7irL8CLX5TG1jYRxExk5H1Ll-xpJqCax3DMkz9dY&mibextid=Zxz2cZ
Nrl303
in
MPN Voice
1 year ago
Big company buys a clinical research company focused on Actinium 225 (and others) FPI-2265
https://www.reuters.com/markets/deals/astrazeneca-buy-fusion-pharma-2-billion-cash-2024-03-19/ Presentation at AACR Annual Meeting 2024 (9th of April): Title: Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed
targeted
alpha
therapy
with FPI-2265 (225Ac-PSMA-I&T) for
https://www.reuters.com/markets/deals/astrazeneca-buy-fusion-pharma-2-billion-cash-2024-03-19/ Presentation at AACR Annual Meeting 2024 (9th of April): Title: Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed
targeted
alpha
therapy
with FPI-2265 (225Ac-PSMA-I&T) for
Maxone73
in
Advanced Prostate Cancer
2 months ago
‘Liquid Radiation’ promises new cancer treatment- DrMichael Hofman, Lead-212 and Lu-177 sounds very promising !
“This project could provide the much-needed chemical and biological foundation to develop first-in-kind theranostics and
targeted
therapy
against the range of cancers.
“This project could provide the much-needed chemical and biological foundation to develop first-in-kind theranostics and
targeted
therapy
against the range of cancers.
David1567
in
Advanced Prostate Cancer
1 year ago
FYI: New data on progression of visceral mets without PSA progression (discordance) and ARAT/docetaxel therapy
This retrospective study using 2008 - 2022 data published in June 2023 reveals a low subset of men (less than 10%) who had early docetaxel [i]or[/i] androgen receptor axis-
targeted
therapy
(ARAT, e.g., abiraterone and enzalutamide) may be susceptible to discordant progression.
This retrospective study using 2008 - 2022 data published in June 2023 reveals a low subset of men (less than 10%) who had early docetaxel [i]or[/i] androgen receptor axis-
targeted
therapy
(ARAT, e.g., abiraterone and enzalutamide) may be susceptible to discordant progression.
SeosamhM
in
Advanced Prostate Cancer
10 months ago
#AskChatGPT - Top ADC Treatment for prostate cancer
The ongoing TAMARACK study aims to further evaluate its efficacy compared to androgen receptor-
targeted
therapy
(https://www.onclive.com/view/adcs-novel-targets-represent-next-wave-of-treatment-advances-in-mcrpc).
The ongoing TAMARACK study aims to further evaluate its efficacy compared to androgen receptor-
targeted
therapy
(https://www.onclive.com/view/adcs-novel-targets-represent-next-wave-of-treatment-advances-in-mcrpc).
God_Loves_Me
in
Advanced Prostate Cancer
19 days ago
CART trial, just FYI
The use of prostate stem cell antigen–
targeted
CAR T-cell
therapy
was well tolerated and produced evidence of anticancer effects in patients with metastatic castration-resistant prostate cancer. https://www.onclive.com/view/psca-
targeted
-car-t-cell-
therapy
-demonstrates-safety-anticancer-activity-in-mcrpc
The use of prostate stem cell antigen–
targeted
CAR T-cell
therapy
was well tolerated and produced evidence of anticancer effects in patients with metastatic castration-resistant prostate cancer. https://www.onclive.com/view/psca-
targeted
-car-t-cell-
therapy
-demonstrates-safety-anticancer-activity-in-mcrpc
Bkraus1
in
Advanced Prostate Cancer
11 months ago
My Oligometastatic PCa Journey Continues...coming up on year 9!
For those that are oligometastatic, here's
a study that suggests the benefits of intermittent hormone
combined with
targeted
radiation versus only continuous hormone
therapy
. My radiation oncologist at MD Anderson is one of the authors of the study.
For those that are oligometastatic, here's
a study that suggests the benefits of intermittent hormone
combined with
targeted
radiation versus only continuous hormone
therapy
. My radiation oncologist at MD Anderson is one of the authors of the study.
JamesAtlanta
in
Advanced Prostate Cancer
4 months ago
Nanocarriers for metastasis, a summary
"Nanocarriers are a hot research area for
targeted
materials in oncology
therapy
.
"Nanocarriers are a hot research area for
targeted
materials in oncology
therapy
.
Maxone73
in
Advanced Prostate Cancer
4 months ago
promising delivery technique for cancer drugs
The NPs exhibited improved pharmacokinetic properties (9.5-fold longer terminal half-life, vs. free docetaxel) and anti-tumor efficacy comparable to Taxotere with negligible systemic toxicity, suggesting zein/CS NPs could be a promising nanoplatform for
targeted
cancer
therapy
.
The NPs exhibited improved pharmacokinetic properties (9.5-fold longer terminal half-life, vs. free docetaxel) and anti-tumor efficacy comparable to Taxotere with negligible systemic toxicity, suggesting zein/CS NPs could be a promising nanoplatform for
targeted
cancer
therapy
.
Maxone73
in
Advanced Prostate Cancer
2 months ago
Heading towards TAVR
I am elderly and have metastatic breast cancer which is kept under control with chemotherapy,
targeted
therapy
and more ever-changing cancer drugs. Six and a half years ago, when first diagnosed, my heart was okay. Now, it seems it is a candidate for TAVR.
I am elderly and have metastatic breast cancer which is kept under control with chemotherapy,
targeted
therapy
and more ever-changing cancer drugs. Six and a half years ago, when first diagnosed, my heart was okay. Now, it seems it is a candidate for TAVR.
jersey-jazz
in
Heart Valve Voice
1 year ago
QUERY RE: LUNG CANCER AND BRAIN METS
My cancer is ALK Positive and I have been on Brigatinab, (which is a
targeted
therapy
treatment) tablet since about April 2022. I also have an infusion 1 x per month of Denosumab.
My cancer is ALK Positive and I have been on Brigatinab, (which is a
targeted
therapy
treatment) tablet since about April 2022. I also have an infusion 1 x per month of Denosumab.
Gymbuddie
in
The Roy Castle Lung Cancer Foundation
1 year ago
1
2
3
4
...
100
Next page
10
20
30
40
50
60
70
80
90
100
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
4427 results
Thyroid UK
2358 results
Endometriosis UK
1850 results
View top 10 communities
Sort by
Most Relevant
Newest